Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Receivables (2016 - 2025)

RedHill Biopharma has reported Receivables over the past 10 years, most recently at $3.3 million for Q4 2025.

  • Quarterly Receivables rose 31.39% to $3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Dec 2025, up 31.39% year-over-year, with the annual reading at $3.3 million for FY2025, 31.39% up from the prior year.
  • Receivables was $3.3 million for Q4 2025 at RedHill Biopharma, down from $5.4 million in the prior quarter.
  • Over five years, Receivables peaked at $36.0 million in Q3 2022 and troughed at $974000.0 in Q2 2024.
  • The 5-year median for Receivables is $23.3 million (2021), against an average of $18.0 million.
  • Year-over-year, Receivables surged 1257.37% in 2021 and then crashed 92.49% in 2023.
  • A 5-year view of Receivables shows it stood at $31.7 million in 2021, then rose by 8.98% to $34.5 million in 2022, then crashed by 92.49% to $2.6 million in 2023, then fell by 2.01% to $2.5 million in 2024, then soared by 31.39% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Receivables are $3.3 million (Q4 2025), $5.4 million (Q2 2025), and $2.5 million (Q4 2024).